|
| |
Ventricular arrhythmia
Ventricular ectopics
- in immediate post-MI period of no prognostic significance
- in post acute phase of MI VEBs associated with poor long-term outcome but
there is no evidence that their suppression with anti-arrhythmics improves
prognosis. Further investigation of underlying ischaemic heart disease indicated
- common in heart failure. Associated with adverse prognosis but again
suppression with anti-arrhythmics does not improve outcome. ACE inhibitors
improve prognosis and decrease frequency of VEBs but former not due to latter
- in otherwise apparently normal individuals very frequent VEBs (> 200/hr)
seems to be associated with increased prevalence of IHD and should prompt some
non-invasive cardiovascular investigations
Ventricular tachycardia
Classification
- can be classified by morphology, duration, underlying mechanisms or
underlying "substrate"
- mechanisms, prognostic significance and management of sustained VT may differ
according to underlying "substrate" (eg coronary artery disease,
mitral valve prolapse, dilated cardiomyopathy)
- definitions used to classify ventricular arrhythmias:
- sustained: > 30 sec duration or requiring intervention for
termination
- non-sustained: 6 beats - 29 sec
- monomorphic: regular rate and consistent beat-to-beat QRS morphology
- polymorphic: frequent changes of QRS morphology and/or axis. If sustained
changes must occur at least every 1-2 sec
- repetitive ventricular beats: 1-5 ventricular beats
Diagnosis of VT
Clinical
- symptoms largely depend on haemodynamic effects of arrhythmia
- history of previous MI and first appearance of tachycardia after infarction
strongly suggest VT
- conversely long history of recurrent tachycardia dating back to childhood and
absence of organic heart disease or the presence of ventricular pre-excitation
suggest SVT
- on examination changes in intensity of 1st heart sound may be detected during
VT and there may be cannon waves in neck due to AV dissociation
ECG criteria
(ECG)
- Is a RS complex present in any precordial lead? If not then diagnosis is VT
- If RS present measure duration of R to S nadir. If >100 ms in any V lead
then diagnosis is VT
- If RS not > 100 ms look for AV dissociation (independent p waves, fusion
beats or capture beats)
- If AV dissociation not present decide whether QRS complexes have a right or
left BBB pattern. If pattern is typical in both V1 and V6 the rhythm is SVT. If
any atypical features rhythm is VT
- Pre-existing complete BBB. Very helpful in diagnosis. eg in patient with
complete RBBB during sinus rhythm, it is highly likely that wide complex
tachycardia with LBBB pattern is VT
- Narrow complex tachycardia. Very rarely VT may be narrow complex. This may be
the case, for example, if, in patient with an anterior wall aneurysm the site of
origin of the VT is in the basal portion of the intraventricular septum.
Arrhythmia may then spread over both ventricles in a similar fashion to the
spread of intraventricular beats
- If in doubt, in patients with structural heart disease it is safer to diagnose
VT and this usually proves to be correct
Non-sustained VT
Definition
- poorly defined
- not a distinct clinical entity
- VT that persists for an arbitrary period of time in the absence of
intervention.
- most usual definition requires minimum of 4 consecutive VEBs and a maximum
duration of 30s
Symptoms
- very variable as it is a poorly defined category
- range from none to syncope
Mechanism
- often polymorphic: this morphology compatible with both re-entry and
triggered automaticity as underlying mechanisms
- monomorphic VT usually due to re-entry
- triggered automaticity not reliably examined by programmed stimulation
- in clinical practice EPS offers assistance in treating some patients: mainly
those in whom the technique can provoke a tachycardia similar to spontaneous
arrhythmia. Sensitivity and specificity modest
Clinical situations
Myocardial infarction
- occurs in as many as 35% of patients in acute phase of MI. Has neither
immediate nor late prognostic significance
- 5-10% in post-acute phase. Probably does have prognostic significance; may be
a marker of susceptibility to sustained VT
- treat symptomatic patients
Reperfusion VT
- usually well tolerated
- may be a marker of good prognosis as may signify recovery of electrically
deranged cells
- no indication for prophylactic anti-arrhythmics
Heart failure
- occurs in many patients with heart failure
- only modest proportion symptomatic
- associated with adverse prognosis. No benefit from treatment with amiodarone
in CHFSTAT study. Amelioration of heart failure may be best strategy
- subgroup analysis of CHFSTAT and GESICA studies suggests that those patients
with heart failure due to idiopathic cardiomyopathy may benefit from amiodarone
Right ventricular dysplasia
- increasingly recognized as aetiological factor for VT in young patients who
initially do not seem to have structural heart disease
- VT characteristically provoked by exercise
- rate may be very rapid and VT usually symptomatic
- very little known about natural history but in some there is a progressive
cardiomyopathic deterioration of the RV with islands of fatty infiltration and
fibrosis that provide ideal conditions for re-entrant VT
- several patterns of VT may occur in each patient
- treat symptomatic patients
Normal individuals
- nothing known of true prevalence or implications
Treatment
- treat symptomatic patients only
- innocuous forms: reassurance may be all that is necessary
- first line: beta blockade. Sotalol 0.5-1.5 mg/kg IV over 5-20 min
- if these fail try other drugs known to be effective against VT. No scientific
way to choose agent but selection should take account of risk/benefit ratio
Sustained VT
Needs to be considered with reference to specific underlying disease
Coronary artery disease
- monomorphic VT most common form of sustained VT
- usually occurs after MI
- arrhythmias originate within or at border zone of damaged myocardium
- underlying mechanism probably re-entry
- ischaemia seems to be less frequently involved in initiation of monomorphic
VT. Tends to present with polymorphic VT or VF instead
Dilated cardiomyopathy
- underlying mechanism less well understood
- prognostic significance of spontaneous VT uncertain
- no evidence that empirical antiarrhythmic therapy is useful for preventing
arrhythmias or for improving survival
- value of programmed ventricular stimulation for assessment of drug efficacy
controversial
Mitral valve prolapse
- sustained VT in patients with clinically significant mitral valve prolapse
rare
- mechanism poorly understood
- response to treatment variable
- some patients respond well to beta-blockers or calcium antagonists while
others do better with class I or III drugs
- programmed stimulation of little clinical value
Hypertrophic cardiomyopathy
- non-sustained VT associated with high risk of sudden death
- occasionally sustained VT recorded
- cellular mechanisms not well understood
Right ventricular cardiomyopathy
- response rate to treatment varies from report to report
- ? sotalol most effective drug
Apparently normal hearts
- patients virtually always < 50 yrs
- usually single VT morphology, typically RBBB and LAD
- ECG during sinus rhythm normal or shows minor ST or T abnormalities
- most patients symptom-free or only have palpitations
- probably does not involve re-entry
- may be initiated during exercise
- may be terminated by verapamil, beta-blockers, or
adenosine
Monitoring effectiveness of treatment
- can be difficult to determine efficacy of treatment and first indication of
treatment failure may be sudden death
- relative merits of programmed stimulation and ambulatory monitoring unclear.
Latter only of value in patients with frequent episodes of VT
Torsades de pointes
Definition
ECG
Causes of long QT
Congenital
- Jervell-Lange-Nielsen syndrome. Autosomal recessive. Long QT and neural
deafness
- Romano-Ward. Autosomal dominant. Normal hearing
- sporadic form. Normal hearing
- Acquired: largely iatrogenic disease with most cases being due to drugs
- Antiarrhythmics
- type 1a and type 3 drugs associated with torsades
- of the type 1a drugs quinidine appears to have the greatest potential for
causing it and is estimated to cause syncope in 0.5-4% of patients as a result
of this tachyarrythmia. Prolongs QT interval in most patients, whether or not
ventricular arrhythmias occur, but significant QT prolongation (500-600 ms) more
often a characteristic of patients with quinidine syncope
- class Ic drugs may also prolong QT interval
- Non-cardiac drugs. Following have been associated with long QT and
torsades:
- phenothiazines especially thioridazine
- tricyclic and occasionally tetracyclic antidepressants
- H1 blockers (eg terfenadine and astemizole; former particularly in
association with erythromycin)
- Metabolic and electrolyte disorders
- hypokalaemia
- hypomagnesaemia
- appears to be synergistic effect between these electrolyte disorders and type
1a drugs
- Bradycardia. VT is a complication of severe bradycardia
- CNS lesions
- intracranial disease, especially subarachnoid haemorrhage, occasionally
produces torsades. Probably due to the influence of autonomic nervous system on
ventricular repolarisation
- Cardiac lesions
- mitral valve prolapse and cardiac ganglionitis may be associated with long QT
Clinical features
Congenital long QT syndrome
- may present in childhood with syncope due to torsades. Often precipitated by
heightened sympathetic tone
- sudden death may occur but frequency of this complication seems to vary
considerably from family to family (<5% to 80%)
- VT may evolve into VF but unlike VF associated with coronary or structural
heart disease often resolves spontaneously to sinus rhythm
Acquired long QT
- principal clinical features are syncope and pre-syncope, often accompanied by
palpitations
- sudden death may occur
Management
Acute
- correct underlying cause if possible
- avoid precipitating drugs
- IV magnesium and temporary atrial or ventricular pacing are initial therapy
- pacing suppresses VT which often does not recur even after cessation of pacing
- isoproterenol (isoprenaline) to increase heart rate can be tried cautiously until pacing
instituted
- prevention of recurrence: beta blockade at maximum tolerated dose, perhaps in
combination with class 1b drug
Further reading
Ben-David J and Zipes DP, Torsades de pointes and proarhythmia. Lancet, 1993;
341:1578-1582
Campbell RWF, Ventricular ectopic beats and non-sustained ventricular
tachycardia. Lancet 1993; 341:1454-1458
Chakko S. Mitrani R. Recognition and management of cardiac arrhythmias: part
II. Ventricular arrhythmias and bradyarrhythmias. J Intensive Care Med, 1998;
68-77
Donovan KD, Hockings BEF. Cardiac arrhythmias. In Oh TE, Intensive Care
Manual, 4th ed.
Shenseca M, Borggrefe M, Haverkamp W et al, Ventricular
tachycardia. Lancet,
1993; 341:1512-1519
© Charles Gomersall July 1999
|